Taha, S., AL-Mahdawi, A. (2023). Reasons of Nonadherence to Treatment in Relapsing Remitting Multiple Sclerosis Patients. , 22(1), 74-80. doi: 10.52573/ipmj.2023.182693
Sarah Yaseen Taha; Akram Mohammad AL-Mahdawi. "Reasons of Nonadherence to Treatment in Relapsing Remitting Multiple Sclerosis Patients". , 22, 1, 2023, 74-80. doi: 10.52573/ipmj.2023.182693
Taha, S., AL-Mahdawi, A. (2023). 'Reasons of Nonadherence to Treatment in Relapsing Remitting Multiple Sclerosis Patients', , 22(1), pp. 74-80. doi: 10.52573/ipmj.2023.182693
Taha, S., AL-Mahdawi, A. Reasons of Nonadherence to Treatment in Relapsing Remitting Multiple Sclerosis Patients. , 2023; 22(1): 74-80. doi: 10.52573/ipmj.2023.182693

Reasons of Nonadherence to Treatment in Relapsing Remitting Multiple Sclerosis Patients

Iraqi Postgraduate Medical Journal
Volume 22, Issue 1, January 2023, Pages 74-80    PDF (355.65 K)
DOI: 10.52573/ipmj.2023.182693
Authors
Sarah Yaseen Taha* 1; Akram Mohammad AL-Mahdawi2
1Baghdad Teaching Hospital/ Medical City, Baghdad, Iraq
2Chairman of the Scientific Council of Neurology, the Iraqi Board for Medical Specializations, Baghdad, Iraq
Abstract
ABSTRACT:
BACKGROUND:
Multiple sclerosis is a chronic disease characterized by inflammation, gliosis, and neuronal loss;    the course can be relapsing-remitting or progressive. 
Treatment with Disease modifying therapy may reduce the number of relapses, slowing down                 the progression of the disease, reducing disability and the number of hospitalizations. 
AIM OF STUDY:
To assess the adherence to medication and to know the causes of non-adherence to treatment in Iraqi patients with Multiple Sclerosis. 
METHODS AND MATERIALS:
Study included 178 patients with relapsing remitting multiple sclerosis from Dr. Saad Al-Witry Hospital for Neurosciences for period started from December 2018 until December 2019. Statistical analysis was tested using Pearson Chi-square test. Statistical significance was considered whenever the P value was equal or less than 0.05.
RESULTS:
It was found that 69(38.8%) patients were adherent to treatment while 109 (62.2%) were not.  There was significant difference between the two groups in the treatment used (P=0.0001).              There were significant differences in non-adherent group between the treatment used in terms of adverse effects, treatment cessation by physician and unavailability of treatment (P=0.015, 0.001 and 0.0001) respectively.
CONCLUSION:
Two thirds of patients were not adherent to treatment, Most common cause was adverse effect mainly in interferon group, also inconvenience and perceived lack of efficacy reported in this groups, unavailable treatment is a reason for patient used Natalizumab, treatment cessation by physician especially  with Fingolimod because of side effect of drug.
 
 
Keywords
Multiple sclerosis; adherence; DMTs
References
  1. Devonshire V. Adherence to Disease Modifying Therapy: Recognizing the barriers and Offering Solutions. Ridgewood, NJ: Delaware Media Group, LLC; 2007.
  2. Sabate E, ed. Adherence to Long Term Therapies: Evidence for Action. Geneva, Switererland; World Health Organization, 2003.
  3. Wick P, Massagli M, Kulkarni A, et al. Use of an online community to develop patient-reported outcome instruments the Multiple Sclerosis Treatment Adherence Questionnaire(MS-TAQ) J Med Internet Res.2011;13:e12.
  4. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology. 2003;61:551–54.
  5. Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult 2005; 11:306–9.
  6. Clerico M, Barbero P, Contessa G, et al. Adherence to interferon-beta treatment and results of therapy switching. J Neurol Sci. 2007;259:104–8.
  7. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology. 1991;41:685–91.
  8. John Wiley & Sons Inc. Biostatistics: A Foundation for Analysis in the Health Sciences. Wayne W Daniel & Chad L Cross; 10th ed. USA; 2013.
  1. John Wiley & Sons Inc. Biostatistic: Basic Concepts & Methodology for the Health Sciences. 9th edition. WW Daniel; 2010.
  2. John Wiley & Sons Inc. Biostatistic: A Foundation for Analysis in the Health Sciences. 8th WW Daniel; 2005.
  3. B Dawson & RG Trapp. Basic & Clinical Biostatistics: 4th edition. Mc Graw Hill; 2004.
  4. Leon Gordis, Saunders Elsevier. Epidemiology. 4th edition. 2009.
  5. Moore ds, mccabe gp & craig ba. Introduction to the Practice of Statistics: extended version Purdue University WH Freeman and Company. 6th edition NewYork; 2009.
  6. Conway DS, Cecilia Vieira M, Thompson NR, et al. Patient-Reported Disease-Modifying Therapy Adherence in the Clinic: A Reliable Metric. Multiple Sclerosis Journal–Experimental, Translational and Clinical; 2018.
  7. Kołtuniuk A, Rosińczuk J. Adherence to disease-modifying therapies in patients with multiple sclerosis. Patient Prefer Adherence; 2018;12:1557–66.
  8. KÖŞKDERELİOĞLU A, GEDİZLİOĞLU M, ORTAN P, Öcek Ö. Evaluation of the adherence to immunmodulatory treatment in patients with multiple sclerosis. Nöro Psikiyatri Arşivi; 2015 ;52:376.
  9. Hauser S, Josephson S. Harrison's Neurology in Clinical Medicine: multiple sclerosis and other demyelinating. 3rd New York; 2013.
  10. Duchovskiene N, Mickeviciene D, Jurkeviciene G, et al. Factors associated with adherence to disease modifying therapy in multiple sclerosis: An observational survey from a referral center in Lithuania; 2017;13:107-11.
  11. Schoor R, Bruce A, Bruce J, et al. Reasons for nonadherence and response to treatment in an adherence intervention trial for relapsing-remitting multiple sclerosis patients. J Clin Psychol; 2018.
  12. Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): A multicenter observational studies on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis. European Journal of Neurology; 2011; 18:69-77.
  13. Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology; 2012; 78:672-80.
  14. Fox EJ, Buckle GJ, Singer B, Singh V, Boster A. Lymphopenia and DMTs for relapsing forms of MS: Considerations for the treating neurologist. Neurology: Clinical Practice; 2019;9:53-63.
  15. Alroughani R, et al: Increasing prevalence and incidence rates of multiple sclerosis in Kuwait; Mult Scler 2014; 20:543-47.
Statistics
Article View: 273
PDF Download: 142


Journal Management System. Powered by iJournalPro.com